Advantages of Intranasal Administration in Treatment of Depression: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Shiguo Sun and Version 1 by Shiguo Sun.

As抑郁症作为现代社会的一种精神疾病，发病率越来越高，治愈率低，复发率高。它已成为世界上最致残的疾病。目前，抑郁症的治疗主要以药物治疗为基础，结合心理治疗、物理治疗等辅助治疗方法。抗抑郁药主要外周给药（口服和静脉注射），起效缓慢。抗抑郁活性成分，如神经肽、天然活性成分和一些化学试剂，受到血脑屏障 a mental disease in modern society, depression shows an increasing occurrence, with low cure rate and high recurrence rate. It has become the most disabling disease in the world. At present, the treatment of depression is mainly based on drug therapy combined with psychological therapy, physical therapy, and other adjuvant therapy methods. Antidepressants are primarily administered peripherally (oral and intravenous) and have a slow onset of action. Antidepressant active ingredients, such as neuropeptides, natural active ingredients, and some chemical agents, are limited by factors such as the blood–brain barrier (BBB), first-pass metabolism, and extensive adverse effects caused by systemic administration. The potential anatomical link between the non-invasive nose–brain pathway and the lesion site of depression may provide a more attractive option for the delivery of antidepressant active ingredients. The purpose of this article is to describe the specific link between intranasal administration and depression, the challenges of intranasal administration, as well as studies of intranasal administration of antidepressant active ingredients.（BBB）、首次通过代谢和全身给药引起的广泛不良反应等因素的限制。非侵入性鼻脑通路与抑郁症病变部位之间的潜在解剖学联系可能为抗抑郁活性成分的输送提供更具吸引力的选择。本文的目的是描述鼻内给药与抑郁症之间的特定联系，鼻内给药的挑战，以及鼻内施用抗抑郁活性成分的研究。

  • depression
  • blood–brain barrier
  • brain targeting
  • antidepressant active ingredients
  • intranasal administration
  • challenges of delivery
Please wait, diff process is still running!

References

  1. S. Evans-Lacko; S. Aguilar-Gaxiola; A. Al-Hamzawi; J. Alonso; C. Benjet; R. Bruffaerts; W. T. Chiu; S. Florescu; G. de Girolamo; O. Gureje; et al.J. M. HaroY. HeC. HuE. G. KaramN. KawakamiS. LeeC. LundV. Kovess-MasfetyD. LevinsonF. Navarro-MateuB. E. PennellN. A. SampsonK. M. ScottH. TachimoriM. Ten HaveM. C. VianaD. R. WilliamsB. J. WojtyniakZ. ZarkovR. C. KesslerS. ChatterjiG. Thornicroft Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys. Psychological Medicine 2017, 48, 1560-1571, 10.1017/s0033291717003336.
  2. Panek, M.; Kawalec, P.; Pilc, A.; Lasoń, W. Developments in the discovery and design of intranasal antidepressants. Expert Opin. Drug Discov. 2020, 15, 1145–1164. https://doi.org/10.1080/17460441.2020.1776697.
  3. Depression and Other Common Mental Disorders: Global Health Estimates. Available online: https://www.who.int/publications/i/item/depression-global-health-estimates (accessed on 17 September 2022).
  4. Illum, L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 2000, 11, 1–18. https://doi.org/10.1016/s0928-0987(00)00087-7.
  5. Kashyap, K.; Shukla, R. Drug Delivery and Targeting to the Brain Through Nasal Route: Mechanisms, Applications and Challenges. Curr. Drug Deliv. 2019, 16, 887–901. https://doi.org/10.2174/1567201816666191029122740.
  6. Mato, Y.L. Nasal route for vaccine and drug delivery: Features and current opportunities. Int. J. Pharm. 2019, 572, 118813. https://doi.org/10.1016/j.ijpharm.2019.118813.
  7. Giunchedi, P.; Gavini, E.; Bonferoni, M.C. Nose-to-brain delivery. Pharmaceutics 2020, 12, 138.
  8. O’Leary, O.F.; Dinan, T.G.; Cryan, J.F. Faster, better, stronger: Towards new antidepressant therapeutic strategies. Eur. J. Pharmacol. 2015, 753, 32–50. https://doi.org/10.1016/j.ejphar.2014.07.046.
  9. Pardridge, W.M. CSF, blood-brain barrier, and brain drug delivery. Expert Opin. Drug Deliv. 2016, 13, 963–975.
  10. Daneman, R.; Prat, A. The blood-brain barrier. Cold Spring Harb. Perspect. Biol. 2015, 7, a020412.
  11. Abbott, N.J.; Patabendige, A.A.K.; Dolman, D.E.M.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010, 37, 13–25. https://doi.org/10.1016/j.nbd.2009.07.030.
  12. Zheng, Y.; Chen, X.; Benet, L.Z. Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. Clin. Pharmacokinet. 2015, 55, 143–167. https://doi.org/10.1007/s40262-015-0310-2.
  13. O'Brien, F.E.; Dinan, T.G.; Griffin, B.T.; Cryan, J.F. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: Clinical significance of in vitro and in vivo findings. Br. J. Pharmacol. 2011, 165, 289–312. https://doi.org/10.1111/j.1476-5381.2011.01557.x.
  14. Brückl, T.M.; Uhr, M. ABCB1 genotyping in the treatment of depression. Pharmacogenomics 2016, 17, 2039–2069. https://doi.org/10.2217/pgs.16.18.
  15. Bicker, J.; Fortuna, A.; Alves, G.; Falcão, A. Nose-to-brain delivery of natural compounds for the treatment of central nervous system disorders Curr. Pharm. Des. 2020, 26, 594–619.
  16. Long, Y.; Yang, Q.; Xiang, Y.; Zhang, Y.; Wan, J.; Liu, S.; Li, N.; Peng, W. Nose to brain drug delivery—A promising strategy for active components from herbal medicine for treating cerebral ischemia reperfusion. Pharmacol. Res. 2020, 159, 104795. https://doi.org/10.1016/j.phrs.2020.104795.
  17. Shringarpure, M.; Gharat, S.; Momin, M.; Omri, A. Management of epileptic disorders using nanotechnology-based strategies for nose-to-brain drug delivery. Expert Opin. Drug Deliv. 2020, 18, 169–185. https://doi.org/10.1080/17425247.2021.1823965.
  18. Wang, Z.; Xiong, G.; Tsang, W.C.; Schätzlein, A.G.; Uchegbu, I.F. Nose-to-brain delivery. J. Pharmacol. Exp. Ther. 2019, 370, 593–601.
  19. Kim, B.-Y.; Bae, J.H. Olfactory Function and Depression: A Meta-Analysis. Ear Nose Throat J. 2022. https://doi.org/10.1177/01455613211056553.
  20. Staszelis, A.; Mofleh, R.; Kocsis, B. The effect of ketamine on delta-range coupling between prefrontal cortex and hippocampus supported by respiratory rhythmic input from the olfactory bulb. Brain Res. 2022, 1791, 147996. https://doi.org/10.1016/j.brainres.2022.147996.
  21. Schwartz, J.S.; Tajudeen, B.A.; Kennedy, D.W. Diseases of the nasal cavity. Handb. Clin. Neurol. 2019, 164, 285–302. https://doi.org/10.1016/b978-0-444-63855-7.00018-6.
  22. Dhuria, S.V.; Hanson, L.R.; Frey, W.H., 2nd. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J. Pharm. Sci. 2010, 99, 1654–1673. https://doi.org/10.1002/jps.21924.
  23. Samaridou, E.; Alonso, M.J. Nose-to-brain peptide delivery—The potential of nanotechnology. Bioorganic Med. Chem. 2018, 26, 2888–2905. https://doi.org/10.1016/j.bmc.2017.11.001.
  24. Rottstädt, F.; Han, P.; Weidner, K.; Schellong, J.; Wolff-Stephan, S.; Strauß, T.; Kitzler, H.; Hummel, T.; Croy, I. Reduced olfactory bulb volume in depression-A structural moderator analysis. Hum. Brain Mapp. 2018, 39, 2573–2582. https://doi.org/10.1002/hbm.24024.
  25. Rottstaedt, F.; Weidner, K.; Strauß, T.; Schellong, J.; Kitzler, H.; Wolff-Stephan, S.; Hummel, T.; Croy, I. Size matters—The olfactory bulb as a marker for depression. J. Affect. Disord. 2017, 229, 193–198. https://doi.org/10.1016/j.jad.2017.12.047.
  26. Cecon, E.; Ivanova, A.; Luka, M.; Gbahou, F.; Friederich, A.; Guillaume, J.; Keller, P.; Knoch, K.; Ahmad, R.; Delagrange, P.; et al. Detection of recombinant and endogenous mouse melatonin receptors by monoclonal antibodies targeting the C‐terminal domain. J. Pineal Res. 2018, 66, e12540. https://doi.org/10.1111/jpi.12540.
  27. Noseda, A.C.D.; Rodrigues, L.S.; Targa, A.D.S.; Ilkiw, J.L.; Fagotti, J.; Dos Santos, P.D.; Cecon, E.; Markus, R.P.; Solimena, M.; Jockers, R.; et al. MT(2) melatonin receptors expressed in the olfactory bulb modulate depressive-like behavior and olfaction in the 6-OHDA model of Parkinson's disease. Eur. J. Pharmacol. 2021, 891, 173722.
  28. Renner, D.B.; Svitak, A.L.; Gallus, N.J.; Ericson, M.E.; Frey, W.H., 2nd; Hanson, L.R. Intranasal delivery of insulin via the olfactory nerve pathway. J. Pharm. Pharmacol. 2012, 64, 1709–1714.
  29. Tan, M.S.A.; Parekh, H.S.; Pandey, P.; Siskind, D.J.; Falconer, J.R. Nose-to-brain delivery of antipsychotics using nanotechnology: A review. Expert Opin. Drug Deliv. 2020, 17, 839–853. https://doi.org/10.1080/17425247.2020.1762563.
  30. Altner, H.; Altner-Kolnberger, I. Freeze-fracture and tracer experiments on the permeability of the zonulae occludentes in the olfactory mucosa of vertebrates. Cell Tissue Res. 1974, 154, 51–59. https://doi.org/10.1007/bf00221071.
  31. Durante, M.A.; Kurtenbach, S.; Sargi, Z.B.; Harbour, J.W.; Choi, R.; Kurtenbach, S.; Goss, G.M.; Matsunami, H.; Goldstein, B.J. Single-cell analysis of olfactory neurogenesis and differentiation in adult humans. Nat. Neurosci. 2020, 23, 323–326. https://doi.org/10.1038/s41593-020-0587-9.
  32. Crowe, T.P.; Greenlee, M.H.W.; Kanthasamy, A.G.; Hsu, W.H. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018, 195, 44–52. https://doi.org/10.1016/j.lfs.2017.12.025.
  33. Trevino, J.; Quispe, R.; Khan, F.; Novak, V. Non-Invasive Strategies for Nose-to-Brain Drug Delivery. J. Clin. Trials 2020, 10, 439.
  34. Lochhead, J.J.; Thorne, R.G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev. 2012, 64, 614–628. https://doi.org/10.1016/j.addr.2011.11.002.
  35. Croy, I.; Hummel, T. Involvement of nasal trigeminal function in human stereo smelling. Proc. Natl. Acad. Sci. USA 2020, 117, 25979–25979. https://doi.org/10.1073/pnas.2016043117.
  36. Lochhead, J.J.; Kellohen, K.L.; Ronaldson, P.T.; Davis, T.P. Distribution of insulin in trigeminal nerve and brain after intranasal administration. Sci. Rep. 2019, 9, 1–9. https://doi.org/10.1038/s41598-019-39191-5.
  37. Kumar, N.N.; Lochhead, J.; Pizzo, M.; Nehra, G.; Boroumand, S.; Greene, G.; Thorne, R.G. Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery. J. Control. Release 2018, 286, 467–484. https://doi.org/10.1016/j.jconrel.2018.08.006.
  38. Pang, Y.; Fan, L.-W.; Carter, K.; Bhatt, A. Rapid transport of insulin to the brain following intranasal administration in rats. Neural Regen. Res. 2019, 14, 1046–1051. https://doi.org/10.4103/1673-5374.250624.
  39. Lochhead, J.; Wolak, D.J.; Pizzo, M.; Thorne, R.G. Rapid Transport within Cerebral Perivascular Spaces Underlies Widespread Tracer Distribution in the Brain after Intranasal Administration. J. Cereb. Blood Flow Metab. 2015, 35, 371–381. https://doi.org/10.1038/jcbfm.2014.215.
  40. Iliff, J.J.; Wang, M.; Liao, Y.; Plogg, B.A.; Peng, W.; Gundersen, G.A.; Benveniste, H.; Vates, G.E.; Deane, R.; Goldman, S.A.; et al. A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β. Sci. Transl. Med. 2012, 4, 147ra111. https://doi.org/10.1126/scitranslmed.3003748.
  41. Pardeshi, C.V.; Rajput, P.V.; Belgamwar, V.S.; Tekade, A.R. Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan. J. Microencapsul. 2011, 29, 103–114. https://doi.org/10.3109/02652048.2011.630106.
  42. Gänger, S.; Schindowski, K. Tailoring Formulations for Intranasal nose-to-brain delivery: A review on architecture, physico-chemical characteristics and mucociliary cearance of the nasal olfactory mucosa. Pharmaceutics 2018, 10, 116.
  43. Schwarz, B.; Merkel, O.M. Nose-to-brain delivery of biologics Ther. Deliv. 2019, 10, 207–210.
  44. Smith, T.D.; Bhatnagar, K.P. Anatomy of the olfactory system. Handb. Clin. Neurol. 2019, 164, 17–28. https://doi.org/10.1016/b978-0-444-63855-7.00002-2.
  45. Olivares, J.; Schmachtenberg, O. An update on anatomy and function of the teleost olfactory system. PeerJ 2019, 7, e7808. https://doi.org/10.7717/peerj.7808.
  46. Palleria, C.; Roberti, R.; Iannone, L.F.; Tallarico, M.; Barbieri, M.A.; Vero, A.; Manti, A.; De Sarro, G.; Spina, E.; Russo, E. Clinically relevant drug interactions between statins and antidepressants. J. Clin. Pharm. Ther. 2019, 45, 227–239. https://doi.org/10.1111/jcpt.13058.
  47. Wyska, E. Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opin. Drug Metab. Toxicol. 2019, 15, 831–847. https://doi.org/10.1080/17425255.2019.1669560.
  48. Erdő, F.; Bors, L.A.; Farkas, D.; Bajza, Á.; Gizurarson, S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 2018, 143, 155–170.
  49. Ruigrok, M.J.; de Lange, E.C. Emerging insights for translational pharmacokinetic and pharmacokinetic-pharmacodynamic studies: Towards prediction of nose-to-brain transport in humans. AAPS J. 2015, 17, 493–505.
  50. Martins, P.P.; Smyth, H.D.; Cui, Z. Strategies to facilitate or block nose-to-brain drug delivery. Int. J. Pharm. 2019, 570, 118635. https://doi.org/10.1016/j.ijpharm.2019.118635.
  51. Iwasaki, S.; Yamamoto, S.; Sano, N.; Tohyama, K.; Kosugi, Y.; Furuta, A.; Hamada, T.; Igari, T.; Fujioka, Y.; Hirabayashi, H.; et al. Direct Drug Delivery of Low-Permeable Compounds to the Central Nervous System Via Intranasal Administration in Rats and Monkeys. Pharm. Res. 2019, 36, 1–14. https://doi.org/10.1007/s11095-019-2613-8.
  52. Marttin, E.; Verhoef, J.C.; Merkus, F.W.H.M. Efficacy, Safety and Mechanism of Cyclodextrins as Absorption Enhancers in Nasal Delivery of Peptide and Protein Drugs. J. Drug Target. 1998, 6, 17–36. https://doi.org/10.3109/10611869808997878.
  53. Li, Y.; Li, J.; Zhang, X.; Ding, J.; Mao, S. Non-ionic surfactants as novel intranasal absorption enhancers: In vitro and in vivo characterization. Drug Deliv. 2014, 23, 2272–2279. https://doi.org/10.3109/10717544.2014.971196.
  54. Rassu, G.; Soddu, E.; Cossu, M.; Brundu, A.; Cerri, G.; Marchetti, N.; Ferraro, L.; Regan, R.F.; Giunchedi, P.; Gavini, E.; et al. Solid microparticles based on chitosan or methyl-beta-cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. J. Control Release 2015, 201, 68–77.
  55. Ozsoy, Y.; Güngör, S. Nasal route: An alternative approach for antiemetic drug delivery. Expert Opin. Drug Deliv. 2011, 8, 1439–1453. https://doi.org/10.1517/17425247.2011.607437.
  56. Liu, L.; Tian, C.; Dong, B.; Xia, M.; Cai, Y.; Hu, R.; Chu, X. Models to evaluate the barrier properties of mucus during drug diffusion. Int. J. Pharm. 2021, 599, 120415. https://doi.org/10.1016/j.ijpharm.2021.120415.
  57. Graff, C.L.; Pollack, G.M. Nasal Drug Administration: Potential for Targeted Central Nervous System Delivery. J. Curr. Chem. Pharm. Sci. 2005, 94, 1187–1195. https://doi.org/10.1002/jps.20318.
  58. Shingaki, T.; Hidalgo, I.J.; Furubayashi, T.; Sakane, T.; Katsumi, H.; Yamamoto, A.; Yamashita, S. Nasal Delivery of P-gp Substrates to the Brain through the Nose–Brain Pathway. Drug Metab. Pharmacokinet. 2011, 26, 248–255. https://doi.org/10.2133/dmpk.dmpk-10-rg-108.
  59. Bourganis, V.; Kammona, O.; Alexopoulos, A.; Kiparissides, C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur. J. Pharm. Biopharm. 2018, 128, 337–362. https://doi.org/10.1016/j.ejpb.2018.05.009.
  60. Dhuria, S.V.; Hanson, L.R.; Frey, W.H., 2nd; Ii, W.H.F. Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System. J. Pharmacol. Exp. Ther. 2008, 328, 312–320. https://doi.org/10.1124/jpet.108.145565.
  61. Pires, A.; Fortuna, A.; Alves, G.; Falcão, A. Intranasal drug delivery: How, why and what for? J. Pharm. Pharm. Sci. 2009, 12, 288–311.
  62. Perez-Caballero, L.; Torres-Sanchez, S.; Bravo, L.; Mico, J.A.; Berrocoso, E. Fluoxetine: A case history of its discovery and preclinical development. Expert Opin. Drug Discov. 2014, 9, 567–578. https://doi.org/10.1517/17460441.2014.907790.
  63. Suwała, J.; Machowska, M.; Wiela-Hojeńska, A. Venlafaxine pharmacogenetics: A comprehensive review. Pharmacogenomics 2019, 20, 829–845. https://doi.org/10.2217/pgs-2019-0031.
  64. Patel, R.G. Nasal Anatomy and Function. Facial Plast. Surg. 2017, 33, 3–8.
  65. Kumar, A.; Pandey, A.N.; Jain, S.K. Nasal-nanotechnology: Revolution for efficient therapeutics delivery. Drug Deliv. 2014, 23, 671–683. https://doi.org/10.3109/10717544.2014.920431.
  66. Costa, C.P.; Moreira, J.; Amaral, M.H.; Lobo, J.M.S.; Silva, A. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J. Control. Release 2019, 295, 187–200. https://doi.org/10.1016/j.jconrel.2018.12.049.
  67. Quintana, D.S.; Westlye, L.T.; Rustan, G.Ø.; Tesli, N.; Poppy, C.L.; Smevik, H.; Tesli, M.; Røine, M.; Mahmoud, R.A.; Smerud, K.T.; et al. Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: A randomized four-way crossover trial with nasal cavity dimension assessment. Transl. Psychiatry 2015, 5, e602.
  68. Mittal, D.; Ali, A.; Shadab; Baboota, S.; Sahni, J.K.; Ali, J. Insights into direct nose to brain delivery: Current status and future perspective. Drug Deliv. 2013, 21, 75–86. https://doi.org/10.3109/10717544.2013.838713.
  69. Djupesland, P.G. Nasal drug delivery devices: Characteristics and performance in a clinical perspective—A review. Drug Deliv. Transl. Res. 2012, 3, 42–62. https://doi.org/10.1007/s13346-012-0108-9.
  70. Tong, X.; Dong, J.; Shang, Y.; Inthavong, K.; Tu, J. Effects of nasal drug delivery device and its orientation on sprayed particle deposition in a realistic human nasal cavity. Comput. Biol. Med. 2016, 77, 40–48. https://doi.org/10.1016/j.compbiomed.2016.08.002.
  71. Warnken, Z.N.; Smyth, H.D.; Watts, A.B.; Weitman, S.; Kuhn, J.G.; Williams, R.O. Formulation and device design to increase nose to brain drug delivery. J. Drug Deliv. Sci. Technol. 2016, 35, 213–222. https://doi.org/10.1016/j.jddst.2016.05.003.
  72. Chen, Y.; Liu, Y.; Xie, J.; Zheng, Q.; Yue, P.; Chen, L.; Hu, P.; Yang, M. Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine. Int. J. Nanomed. 2020, 15, 10435–10451. https://doi.org/10.2147/ijn.s265659.
  73. Agrawal, M.; Saraf, S.; Saraf, S.; Dubey, S.K.; Puri, A.; Gupta, U.; Kesharwani, P.; Ravichandiran, V.; Kumar, P.; Naidu, V.; et al. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. J. Control. Release 2020, 327, 235–265. https://doi.org/10.1016/j.jconrel.2020.07.044.
  74. Kanwar, N.; Sinha, V.R. In Situ Forming Depot as Sustained-Release Drug Delivery Systems.. Crit. Rev. Ther. Drug Carr. Syst. 2019, 36, 93–136. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2018025013.
  75. Kapoor, D.N.; Bhatia, A.; Kaur, R.; Sharma, R.; Kaur, G.; Dhawan, S. PLGA: A unique polymer for drug delivery. Ther. Deliv. 2015, 6, 41–58. https://doi.org/10.4155/tde.14.91.
  76. Desai, K.G. Chitosan Nanoparticles Prepared by Ionotropic Gelation: An Overview of Recent Advances. Crit. Rev. Ther. Drug Carr. Syst. 2016, 33, 107–158. https://doi.org/10.1615/critrevtherdrugcarriersyst.2016014850.
  77. Prabaharan, M. Chitosan-based nanoparticles for tumor-targeted drug delivery. Int. J. Biol. Macromol. 2015, 72, 1313–1322. https://doi.org/10.1016/j.ijbiomac.2014.10.052.
  78. Mohebbi, S.; Nezhad, M.N.; Zarrintaj, P.; Jafari, S.H.; Gholizadeh, S.S.; Saeb, M.R.; Mozafari, M. Chitosan in Biomedical Engineering: A Critical Review. Curr. Stem Cell Res. Ther. 2019, 14, 93–116. https://doi.org/10.2174/1574888x13666180912142028.
  79. Jana, S.; Sen, K.K.; Gandhi, A. Alginate Based Nanocarriers for Drug Delivery Applications. Curr. Pharm. Des. 2016, 22, 3399–3410. https://doi.org/10.2174/1381612822666160510125718.
  80. Tønnesen, H.H.; Karlsen, J. Alginate in Drug Delivery Systems. Drug Dev. Ind. Pharm. 2002, 28, 621–630. https://doi.org/10.1081/ddc-120003853.
  81. Severino, P.; Da Silva, C.F.; Andrade, L.N.; de Lima Oliveira, D.; Campos, J.; Souto, E.B. Alginate Nanoparticles for Drug Delivery and Targeting. Curr. Pharm. Des. 2019, 25, 1312–1334. https://doi.org/10.2174/1381612825666190425163424.
  82. Thai, H.; Nguyen, C.T.; Thach, L.T.; Tran, M.T.; Mai, H.D.; Nguyen, T.T.T.; Le, G.D.; Van Can, M.; Tran, L.D.; Bach, G.L.; et al. Characterization of chitosan/alginate/lovastatin nanoparticles and investigation of their toxic effects in vitro and in vivo. Sci. Rep. 2020, 10, 909–915. https://doi.org/10.1038/s41598-020-57666-8.
  83. Reig-Vano, B.; Tylkowski, B.; Montané, X.; Giamberini, M. Alginate-based hydrogels for cancer therapy and research. Int. J. Biol. Macromol. 2020, 170, 424–436. https://doi.org/10.1016/j.ijbiomac.2020.12.161.
  84. Ahmad, E.; Feng, Y.; Qi, J.; Fan, W.; Ma, Y.; He, H.; Xia, F.; Dong, X.; Zhao, W.; Lu, Y.; et al. Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles. Nanoscale 2016, 9, 1174–1183. https://doi.org/10.1039/c6nr07581a.
  85. Bahadur, S.; Pardhi, D.M.; Rautio, J.; Rosenholm, J.M.; Pathak, K. Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders. Pharmaceutics 2020, 12, 1230. https://doi.org/10.3390/pharmaceutics12121230.
  86. Bonferoni, M.C.; Rossi, S.; Sandri, G.; Ferrari, F.; Gavini, E.; Rassu, G.; Giunchedi, P. Nanoemulsions for "nose-to-brain" drug delivery. Pharmaceutics 2019, 11, 1230.
  87. Rinaldi, F.; Oliva, A.; Sabatino, M.; Imbriano, A.; Hanieh, P.N.; Garzoli, S.; Mastroianni, C.M.; De Angelis, M.; Miele, M.C.; Arnaut, M.; et al. Antimicrobial Essential Oil Formulation: Chitosan Coated Nanoemulsions for Nose to Brain Delivery. Pharmaceutics 2020, 12, 678. https://doi.org/10.3390/pharmaceutics12070678.
  88. Pandey, V.; Kohli, S. Lipids and Surfactants: The Inside Story of Lipid-Based Drug Delivery Systems. Crit. Rev. Ther. Drug Carr. Syst. 2018, 35, 99–155. https://doi.org/10.1615/critrevtherdrugcarriersyst.2018016710.
  89. Urquhart, A.J.; Eriksen, A.Z. Recent developments in liposomal drug delivery systems for the treatment of retinal diseases. Drug Discov. Today 2019, 24, 1660–1668. https://doi.org/10.1016/j.drudis.2019.04.004.
  90. Pattni, B.S.; Chupin, V.V.; Torchilin, V.P. New Developments in Liposomal Drug Delivery. Chem. Rev. 2015, 115, 10938–10966. https://doi.org/10.1021/acs.chemrev.5b00046.
  91. Natsheh, H.; Touitou, E. Phospholipid Magnesome—A nasal vesicular carrier for delivery of drugs to brain. Drug Deliv. Transl. Res. 2018, 8, 806–819. https://doi.org/10.1007/s13346-018-0503-y.
  92. Natsheh, H.; Touitou, E. Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties. Molecules 2020, 25, 2959. https://doi.org/10.3390/molecules25132959.
  93. Touitou, E.; Duchi, S.; Natsheh, H. A new nanovesicular system for nasal drug administration. Int. J. Pharm. 2020, 580, 119243. https://doi.org/10.1016/j.ijpharm.2020.119243.
  94. Tapeinos, C.; Battaglini, M.; Ciofani, G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J. Control. Release 2017, 264, 306–332. https://doi.org/10.1016/j.jconrel.2017.08.033.
  95. Garcês, A.; Amaral, M.H.; Sousa Lobo, J.M.; Silva, A.C. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review. Eur. J. Pharm. Sci. 2018, 112, 159–167. https://doi.org/10.1016/j.ejps.2017.11.023.
  96. Czajkowska-Kośnik, A.; Szekalska, M.; Winnicka, K. Nanostructured lipid carriers: A potential use for skin drug delivery systems. Pharmacol. Rep. 2018, 71, 156–166. https://doi.org/10.1016/j.pharep.2018.10.008.
  97. Khosa, A.; Reddi, S.; Saha, R.N. Nanostructured lipid carriers for site-specific drug delivery. Biomed. Pharmacother. 2018, 103, 598–613. https://doi.org/10.1016/j.biopha.2018.04.055.
  98. Cayero-Otero, M.D.; Gomes, M.J.; Martins, C.; Álvarez-Fuentes, J.; Fernández-Arévalo, M.; Sarmento, B.; Martín-Banderas, L. In vivo biodistribution of venlafaxine-PLGA nanoparticles for brain delivery: Plain vs. functionalized nanoparticles. Expert Opin. Drug Deliv. 2019, 16, 1413–1427.
  99. Haque, S.; Shadab; Fazil, M.; Kumar, M.; Sahni, J.K.; Ali, J.; Baboota, S. Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation. Carbohydr. Polym. 2012, 89, 72–79. https://doi.org/10.1016/j.carbpol.2012.02.051.
  100. Tong, G.-F.; Qin, N.; Sun, L.-W. Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. Saudi Pharm. J. 2016, 25, 844–851. https://doi.org/10.1016/j.jsps.2016.12.003.
  101. Ahmed, S.; Gull, A.; Aqil, M.; Ansari, M.D.; Sultana, Y. Poloxamer-407 thickened lipid colloidal system of agomelatine for brain targeting: Characterization, brain pharmacokinetic study and behavioral study on Wistar rats. Colloids Surfaces B: Biointerfaces 2019, 181, 426–436. https://doi.org/10.1016/j.colsurfb.2019.05.016.
  102. Fatouh, A.M.; Elshafeey, A.H.; Abdelbary, A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: Formulation, optimization and in vivo pharmacokinetics. Drug Des. Dev. Ther. 2017, 11, 1815–1825. https://doi.org/10.2147/DDDT.S102500.
  103. Alam, M.I.; Baboota, S.; Ahuja, A.; Ali, M.; Ali, J.; Sahni, J.K. Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood. Drug Deliv. 2013, 20, 247–251. https://doi.org/10.3109/10717544.2013.822945.
  104. Alam, M.I.; Baboota, S.; Ahuja, A.; Ali, M.; Ali, J.; Sahni, J.K.; Bhatnagar, A. Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. Int. J. Pharm. 2014, 470, 99–106. https://doi.org/10.1016/j.ijpharm.2014.05.004.
  105. Elsenosy, F.M.; Abdelbary, G.A.; Elshafeey, A.H.; Elsayed, I.; Fares, A.R. Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. Int. J. Nanomed. 2020, 15, 9517–9537. https://doi.org/10.2147/ijn.s277352.
  106. Pandey, Y.R.; Kumar, S.; Gupta, B.K.; Ali, J.; Baboota, S. Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: Formulation, behavioural and biochemical estimation. Nanotechnology 2015, 27, 25102. https://doi.org/10.1088/0957-4484/27/2/025102.
  107. Motaleb, M.A.; Ibrahim, I.T.; Sayyed, M.E.; Awad, G.A.S. (131)I-trazodone: Preparation, quality control and in vivo biodis-tribution study by intranasal and intravenous routes as a hopeful brain imaging radiopharmaceutical. Rev. Esp. Med. Nucl. Imagen Mol. 2017, 36, 371–376.
  108. Shah, B.; Khunt, D.; Misra, M.; Padh, H. Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration. Eur. J. Pharm. Sci. 2016, 91, 196–207. https://doi.org/10.1016/j.ejps.2016.05.008.
  109. Naik, A.; Nair, H. Formulation and Evaluation of Thermosensitive Biogels for Nose to Brain Delivery of Doxepin. BioMed Res. Int. 2014, 2014, 1–10. https://doi.org/10.1155/2014/847547.
  110. Eduardo, T.Q.; Angela, A.; Mateo, L.; Melanie, L.Z.; Valentina, P.F.; David, C.; Estefania, C.; Natalia, R.S.; Andrés, V.C.; Angel, R.O.; et al. Ketamine for resistant depression: A scoping review. Actas Esp. Psiquiatr. 2022, 50, 144–159.
  111. Yavi, M.; Lee, H.; Henter, I.D.; Park, L.T.; Zarate, C.A., Jr. Ketamine treatment for depression: A review. Discov. Ment. Heal. 2022, 2, 1–14. https://doi.org/10.1007/s44192-022-00012-3.
  112. Gadhave, D.; Tupe, S.; Tagalpallewar, A.; Gorain, B.; Choudhury, H.; Kokare, C. Nose-to-brain delivery of amisul-pride-loaded lipid-based poloxamer-gellan gum nanoemulgel: In vitro and in vivo pharmacological studies. Int. J. Pharm. 2021, 607, 121050. https://doi.org/10.1016/j.ijpharm.2021.121050.
  113. Kumbhar, S.A.; Kokare, C.R.; Shrivastava, B.; Gorain, B.; Choudhury, H. Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. J. Pharm. Sci. 2021, 110, 1761–1778. https://doi.org/10.1016/j.xphs.2021.01.021.
  114. Sawant, K.; Pandey, A.; Patel, S. Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharma-cokinetics. Mater. Sci. Eng. C Mater. Biol. Appl. 2016, 66, 230–243. https://doi.org/10.1016/j.msec.2016.04.089.
  115. Sridhar, V.; Gaud, R.; Bajaj, A.; Wairkar, S. Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease. Nanomedicine 2018, 14, 2609–2618.
  116. Sridhar, V.; Wairkar, S.; Gaud, R.; Bajaj, A.; Meshram, P. Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease. J. Drug Target 2018, 26, 150–161.
  117. Nedelcovych, M.T.; Gadiano, A.J.; Wu, Y.; Manning, A.A.; Thomas, A.G.; Khuder, S.S.; Yoo, S.-W.; Xu, J.; McArthur, J.C.; Haughey, N.J.; et al. Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ACS Chem. Neurosci. 2017, 9, 809–816. https://doi.org/10.1021/acschemneuro.7b00434.
  118. Ren, G.; Xue, P.; Wu, B.; Yang, F.; Wu, X. Intranasal treatment of lixisenatide attenuated emotional and olfactory symptoms via CREB-mediated adult neurogenesis in mouse depression model. Aging 2021, 13, 3898–3908. https://doi.org/10.18632/aging.202358.
  119. Sasaki-Hamada, S.; Nakamura, R.; Nakao, Y.; Akimoto, T.; Sanai, E.; Nagai, M.; Horiguchi, M.; Yamashita, C.; Oka, J.-I. Antidepressant-like effects exerted by the intranasal administration of a glucagon-like peptide-2 derivative containing cell-penetrating peptides and a penetration-accelerating sequence in mice. Peptides 2017, 87, 64–70. https://doi.org/10.1016/j.peptides.2016.11.013.
  120. Ma, X.-C.; Liu, P.; Zhang, X.-L.; Jiang, W.-H.; Jia, M.; Wang, C.-X.; Dong, Y.-Y.; Dang, Y.-H.; Gao, C.-G. Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: A Potential Promising Therapy Strategy for Major Depressive Disorder. Sci. Rep. 2016, 6, 22404. https://doi.org/10.1038/srep22404.
  121. Chen, C.; Dong, Y.; Liu, F.; Gao, C.; Ji, C.; Dang, Y.; Ma, X.; Liu, Y. A Study of Antidepressant Effect and Mechanism on Intranasal Delivery of BDNF-HA2TAT/AAV to Rats with Post-Stroke Depression. Neuropsychiatr. Dis. Treat. 2020, 16, 637–649. https://doi.org/10.2147/ndt.s227598.
  122. Liu, F.; Liu, Y.-P.; Lei, G.; Liu, P.; Chu, Z.; Gao, C.-G.; Dang, Y.-H. Antidepressant effect of recombinant NT4-NAP/AAV on social isolated mice through intranasal route. Oncotarget 2016, 8, 10103–10113. https://doi.org/10.18632/oncotarget.14356.
  123. Ma, X.-C.; Chu, Z.; Zhang, X.-L.; Jiang, W.-H.; Jia, M.; Dang, Y.-H.; Gao, C.-G. Intranasal Delivery of Recombinant NT4-NAP/AAV Exerts Potential Antidepressant Effect. Neurochem. Res. 2016, 41, 1375–1380. https://doi.org/10.1007/s11064-016-1841-0.
  124. Jiang, J.; Peng, Y.; Liang, X.; Li, S.; Chang, X.; Li, L.; Chang, M. Centrally administered cortistation-14 induces antidepres-sant-like effects in mice via mediating ghrelin and GABA(A) receptor signaling pathway. Front. Pharmacol. 2018, 9, 767.
  125. Serova, L.; Laukova, M.; Alaluf, L.; Pucillo, L.; Sabban, E. Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model. Eur. Neuropsychopharmacol. 2014, 24, 142–147. https://doi.org/10.1016/j.euroneuro.2013.11.007.
  126. Oh, J.-Y.; Liu, Q.F.; Hua, C.; Jeong, H.J.; Jang, J.-H.; Jeon, S.; Park, S.J.A.H.-J. Intranasal Administration of Mela-nin-Concentrating Hormone Reduces Stress-Induced Anxiety- and Depressive-Like Behaviors in Rodents. Exp. Neurobiol. 2020, 29, 453–469. https://doi.org/10.5607/en20024.
  127. Shi, C.-G.; Wang, L.-M.; Wu, Y.; Wang, P.; Gan, Z.-J.; Lin, K.; Jiang, L.-X.; Xu, Z.-Q.; Fan, M. Intranasal Administration of Nerve Growth Factor Produces Antidepressant-Like Effects in Animals. Neurochem. Res. 2010, 35, 1302–1314. https://doi.org/10.1007/s11064-010-0183-6.
  128. Xu, D.; Qiao, T.; Wang, Y.; Wang, Q.-S.; Cui, Y.-L. Alginate nanogels-based thermosensitive hydrogel to improve antide-pressant-like effects of albiflorin via intranasal delivery. Drug Deliv. 2021, 28, 2137–2149. https://doi.org/10.1080/10717544.2021.1986604.
  129. Wang, Q.-S.; Li, K.; Gao, L.-N.; Zhang, Y.; Lin, K.-M.; Cui, Y.-L. Intranasal delivery of berberine via in situ thermoresponsive hydrogels with non-invasive therapy exhibits better antidepressant-like effects. Biomater. Sci. 2020, 8, 2853–2865. https://doi.org/10.1039/c9bm02006c.
  130. Xu, D.; Qiu, C.; Wang, Y.; Qiao, T.; Cui, Y.-L. Intranasal co-delivery of berberine and evodiamine by self-assembled ther-mosensitive in-situ hydrogels for improving depressive disorder. Int. J. Pharm. 2021, 603, 120667. https://doi.org/10.1016/j.ijpharm.2021.120667.
  131. Zhang, K.; Lei, N.; Li, M.; Li, J.; Li, C.; Shen, Y.; Guo, P.; Xiong, L.; Xie, Y. Cang-Ai Volatile Oil Ameliorates Depressive Be-havior Induced by Chronic Stress Through IDO-Mediated Tryptophan Degradation Pathway. Front. Psychiatry 2021, 12, 791991. https://doi.org/10.3389/fpsyt.2021.791991.
  132. Chen, B.; Li, J.; Xie, Y.; Ming, X.; Li, G.; Wang, J.; Li, M.; Li, X.; Xiong, L. Cang-ai volatile oil improves depressive-like behaviors and regulates DA and 5-HT metabolism in the brains of CUMS-induced rats. J. Ethnopharmacol. 2019, 244, 112088. https://doi.org/10.1016/j.jep.2019.112088.
  133. Xu, D.; Lu, Y.-R.; Kou, N.; Hu, M.-J.; Wang, Q.-S.; Cui, Y.-L. Intranasal delivery of icariin via a nanogel-thermoresponsive hydrogel compound system to improve its antidepressant-like activity. Int. J. Pharm. 2020, 586, 119550. https://doi.org/10.1016/j.ijpharm.2020.119550.
  134. Hu, W.; Xie, G.; Zhou, T.; Tu, J.; Zhang, J.; Lin, Z.; Zhang, H.; Gao, L. Intranasal administration of white tea alleviates the olfactory function deficit induced by chronic unpredictable mild stress. Pharm. Biol. 2020, 58, 1230–1237. https://doi.org/10.1080/13880209.2020.1855213.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback